The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae | Zendy

Pranita D. Tamma | Zendy; Sonya Tang Girdwood | Zendy; Ravindra Gopaul | Zendy; Tsigereda Tekle | Zendy; Ava A. Roberts | Zendy; Anthony Harris | Zendy; Sara E. Cosgrove | Zendy; Karen C. Carroll | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae

Author(s) -

Pranita D. Tamma,

Sonya Tang Girdwood,

Ravindra Gopaul,

Tsigereda Tekle,

Ava A. Roberts,

Anthony Harris,

Sara E. Cosgrove,

Karen C. Carroll

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit395

Subject(s) - cefepime , medicine , meropenem , cefotetan , enterobacter , cephalosporin , ertapenem , tigecycline , odds ratio , microbiology and biotechnology , antibiotics , antibiotic resistance , biology , imipenem , biochemistry , escherichia coli , gene

AmpC β-lactamase-producing organisms are associated with significant morbidity and mortality. Induction of resistance to third-generation cephalosporins after exposure to these agents complicates treatment options and carbapenems are considered optimal therapy. The role of cefepime, however, remains unclear. Our objective was to compare clinical outcomes for patients receiving cefepime compared with meropenem for invasive infections caused by organisms expressing AmpC β-lactamases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research